Podcasts about Life Technologies

In this episode of Life Science Success, host Don Davis interviews Bill Enright, a seasoned biotech executive with over 30 years of experience.   They discuss Bill's career journey from pre-med student to CEO roles, his experiences with companies like Barinthus Bio, Altimmune, GenVec, and Life Technologies, and his strategic insights on leading biotech firms. Bill shares valuable leadership lessons, the importance of corporate culture, and the role of innovation in advancing precision immunotherapies.   He also highlights his board position at Bullfrog AI and how AI is transforming the life sciences landscape. Tune in to learn about Bill's inspiring path and the future of biotech.     00:00 Introduction to Life Science Success Podcast 00:41 Sponsor Message: D3 Digital Media Marketing 01:28 Guest Introduction: Bill Enright 01:49 Bill Enright's Career Journey 09:38 Challenges and Resilience in Biotech 14:38 Board Membership and AI in Life Sciences 18:04 Barinthus Bio: Mission and Projects 25:54 Leadership and Corporate Culture 34:28 Closing Remarks and Podcast Information  

In this episode, we welcome Dr. Brück Wolfram Manuel who shares his international perspectives on food and health microbiology. We'll discuss infant nutrition and the unique field of 'Foodomics.' Expect to learn about new food trends such as sustainable proteins and turning food waste into something good for us and the planet! Brück Wolfram Manuel studied microbiology in Minnesota and Manchester (UK). In 2003, he finished his Ph.D. with Prof. Glenn Gibson on the influence of prebiotic milk peptides on infant health. He joined the Institute of Life Technologies as head of the microbiology laboratories in 2014 and in April he directed a national competence center for research application on “sustainable diets and precision nutrition”. On This Episode You Will Learn: Research Regarding Infant Nutrition Nutritional and Environmental Benefits of Bioactive Compounds Personalized Nutrition Patterns from Country-to-Country Connect with Yumlish! Website Instagram Twitter Facebook LinkedIn YouTube Connect with Brück! Brück 's Website LinkedIn --- Send in a voice message: https://podcasters.spotify.com/pod/show/yumlish/message

Lisa V. Sellers, PhD, CEO of Vector Laboratories, is an accomplished leader and mentor in life sciences with more than 20 years of experience in the industry. Sellers drives expansion and business strategies for Vector Laboratories, a trusted reagent and critical component manufacturing partner that empowers biopharma, life science tools and diagnostics companies to accelerate their ability to provide value to their customers. Sellers has a stellar track record of spearheading successful business strategies based on unmet market opportunities, while prioritizing the development of a people-first work environment. This winning combination has created unstoppable forward momentum at Vector Laboratories. Before joining Vector Laboratories, Sellers provided consulting services for numerous life science companies to guide them in accelerating product development and commercialization to enter new markets. Sellers has served in executive and senior management roles in marketing, sales, and specific product lines for companies such as Thermo Fisher Scientific, 10x Genomics, Life Technologies, and Applied Biosystems, among others.  While Sellers has earned notable success as a top life science industry expert, she has always believed in the importance of giving back. Sellers serves as an Advisory Board Member with the LEAD Scholars Program at Santa Clara University, a board member with Notre Dame Belmont High School, and an Advisory Board Member, Master of Biotechnology at San Jose State University. She has a personal passion for coaching professionals to navigate job choices in STEM to achieve their potential and to provide the utmost in career fulfillment. As such, Sellers has been a speaker at ISPE, Navigating Your Career Amidst Uncertainty in Dec 2020; Women in Product, SF Bay Area, for Go-to Market Series in May 2019; and was featured in CMO.com, Best Leadership Advice I Ever Received publication in Feb 2019. Sellers was also named A Women of Influence in 2022 by the Silicon Valley Business Journal.  Sellers earned a PhD in Chemistry from the University of Colorado Boulder and a BS in Chemistry, ACS Certified from Santa Clara University. --- Support this podcast: https://podcasters.spotify.com/pod/show/freeman-means-business/support

Irish engineers are incredibly creative thinkers and innovators, but it's a big leap going from innovator to entrepreneur, and taking an idea you might have to market. Today we hear from a prominent engineer with a fascinating career history, which took her from aeronautical engineering into the biomedical space. We'll be finding out how she looks at problems, overcomes obstacles, where she sees innovation and opportunity, and getting some great advice for any engineers who are thinking of launching their own business. Our guest is CEO of Altratech and the Assistant Director of the Stokes Research Institute at University of Limerick, Dr. Tara Dalton.THINGS WE SPOKE ABOUTTransitioning through different disciplines of engineering The benefits of working within interdisciplinary teamsLearning to ‘skate where the puck is' Being aware of trends and spotting gaps in the market Striving for progress over perfection and asking for help GUEST DETAILSDr Tara Dalton, CEO of Altratech and Assistant Director of the Stokes Research Institute in the Department of Mechanical and Aeronautical Engineering at the University of Limerick.Dr Dalton is a fellow of the Irish Academy of Engineers. She is one of the founders of Stokes Bio – a spin-out company that was sold to Life Technologies that developed high throughput microfluidic instruments for PCR. Her research interest is in the development of microfluidic devices for biological assays. She has graduated 20 PhD Students, published over 100 refereed papers and has over 50 granted patent and patent applications.https://altratech.com/ https://ul.ie/research/dr-tara-dalton MORE INFORMATIONLooking for ways to explore or advance a career in the field of engineering? Visit Engineers Ireland to learn more about the many programs and resources on offer. https://www.engineersireland.ie/   Engineers Journal AMPLIFIED is produced by DustPod.io for Engineers Ireland.QUOTESIn my mind, in engineering, you don't want to be at the cutting edge of absolute new science. You want to be just behind it, so you can help people with that science. - Tara Dalton When you work with interdisciplinary team, and I work with medics, physicists, chemists or even with other entrepreneurs, it's just amazing, because I find that everybody wants to help you be better. Nobody, at least in my experience, gatekeeps their knowledge. - Tara DaltonSkate where the puck is, right. It didn't matter that I had this great product, but to get venture capital funding, that was never going to happen, because it wasn't in that ecosystem at the time. So that was one really big learning lesson. - Tara Dalton Ask for help. Everybody, ask for help. Go talk to people, go talk to Enterprise Ireland, go talk to lawyers, go talk to VCs. Don't go saying I want, want, want, just say, What should I do? How could you help me? You'd be surprised how many people will give you their time. - Tara Dalton KEYWORDS#engineering #problemsolving #entrepreneurship #biomedical #aeronauticalengineering #science

ABOUT THE AUTHOR: Mark Springer has three decades of experience as a senior-level writer, and editor of technical and scientific documents. He also has crafted promotional content for the medical device, biotechnology, and life science industries. For the past seven years, he has been working for Gilead Sciences, including the last five as the manager and technical editor in labeling operations. Prior to that, he served for two years, as the senior technical editor for BD Biosciences, editing all customer-read documents to meet factual, legal and regulation requirements. He received a Special Achievement Recognition Award there. His career began as a senior technical writer and managing editor of all technical publications for change management software at a startup company. The biggest portion of his career consisted of 19 years at Life Technologies, where his positions varied from senior science writer in brand marketing, senior manager in public relations, to senior writer in technical communications. He is the author of Flesh Becomes Words, his debut novel that blends science fiction with spirituality. Along with a colleague, he developed an online magazine in the late 1990s called BioBeat Online Magazine. For about six years, he wrote articles for this publication and other trade publications that were associated with a life sciences company in the Bay Area. The articles were related to significant research and medical applications related to the use of DNA sequencing and genetic analysis technologies. He and his colleague won numerous Apex Publication awards for the content over this six-year period. Springer graduated from University of California at Berkeley with a BA, double-majoring in Cell Biology and English Literature. He is deeply devoted to his faith, reading the Bible two to three hours daily. His book reflects both his science acumen and his dedication to faith. Born in Albany, NY, he now resides in San Mateo, California.

ABOUT THE AUTHOR: Mark Springer has three decades of experience as a senior-level writer, and editor of technical and scientific documents. He also has crafted promotional content for the medical device, biotechnology, and life science industries. For the past seven years, he has been working for Gilead Sciences, including the last five as the manager and technical editor in labeling operations. Prior to that, he served for two years, as the senior technical editor for BD Biosciences, editing all customer-read documents to meet factual, legal and regulation requirements. He received a Special Achievement Recognition Award there. His career began as a senior technical writer and managing editor of all technical publications for change management software at a startup company. The biggest portion of his career consisted of 19 years at Life Technologies, where his positions varied from senior science writer in brand marketing, senior manager in public relations, to senior writer in technical communications. He is the author of Flesh Becomes Words, his debut novel that blends science fiction with spirituality. Along with a colleague, he developed an online magazine in the late 1990s called BioBeat Online Magazine. For about six years, he wrote articles for this publication and other trade publications that were associated with a life sciences company in the Bay Area. The articles were related to significant research and medical applications related to the use of DNA sequencing and genetic analysis technologies. He and his colleague won numerous Apex Publication awards for the content over this six-year period. Springer graduated from University of California at Berkeley with a BA, double-majoring in Cell Biology and English Literature. He is deeply devoted to his faith, reading the Bible two to three hours daily. His book reflects both his science acumen and his dedication to faith. Born in Albany, NY, he now resides in San Mateo, California

On today's show, independent researchers and writers John Beaudoin Sr. and Kevin McKernan review Steve Kirsch's recent 'data bombshell' speech at MIT and take turns sharing their expert analysis of the pandemic and the subsequent jabs. John and Kevin each tell their remarkable stories of how they were able to recognize the scam of the pandemic early on, as a result of their respective fields of study. Also, John shares a profound and personal story, and Kevin explains some of his pioneering scientific work in the field of therapeutic cannabis. GUEST 1 OVERVIEW: John Paul Beaudoin, Sr. is an American author and father of three men for whom he spent all of his meaningful life caring. John has a Master's degree in Business Administration and a Bachelor's degree in Computer & Systems Engineering. After more than thirty (>30) years developing and executing campaigns for contracts in the electronics and semiconductors research and development industry, John lost his eldest son at twenty (20) years old in a motorcycle accident. Two (2) years afterward, the covid era began. John simply wanted truth and could not find it in government data, media announcements, press releases, or local conversations. He sought a signal amongst the noise. John knew that things were not as we were programmed to believe. Having been in sales and marketing, he recognized the tactics used against the populace. Three (3) and four (4) word catch phrases were repeated ad nauseam on television and social media. This is programming, marketing, advertising, manipulation, propaganda. “Two weeks to flatten the curve” “Safe and effective” “I wear my mask for you” “Six feet” “Antivaxers are selfish” “Don't kill grandma” “Correlation doesn't equal causation” John recognizes these mass manipulation tactics and strategies because he sees first-hand the outcome of such manipulation. He sees the world from a viewpoint of interrelated systems. When orders were given to lock down, social distance, mask, or vaccinate, John knew immediately the negative externalities that would ensue. Some people are frail in physical and mental health. Stark societal changes will maim or kill those at the margins of health. Given John's horizontal aptitude, he was a good fit for the problem. His insight is gleaned from his years of problem solving from an engineering point of view. This includes a unique and cursory knowledge across a wide range of disciplines including : psychology, sociology, economics, law, finance, accounting, physical sciences, electrical engineering. John is one of a handful of people with the record-level source data and the systems-level vision to pull it all together into a broad understanding of how this covid era came to be. https://substack.com/@coquindechien https://twitter.com/JohnBeaudoinSr GUEST 2 OVERVIEW: Kevin McKernan is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature. Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening. https://substack.com/@kevinmckernan https://twitter.com/Kevin_McKernan

How clear are you with your team on your purpose as a leader and how they're supposed to deliver on it? As an effective leader, you must be clear on what your home run looks like and communicate it to your team to achieve success.In this episode of the She Leads Now Podcast, Ann Sullivan talks about her HR career in corporate, transitioning to entrepreneurship, and how she's established herself as an expert. Ann has held executive-level human resources, organization development, and training roles with Life Technologies, PepsiCo, YUM! Brands and Callaway Golf. Her experience as a generalist and specialist in corporate and field positions across highly competitive, dynamic industries makes her a uniquely qualified and versatile professional.Key Takeaways:The importance of advocating for ourselves and each other as women in leadership spaces.How to show up as an authentic expert unafraid to tell the truth when working as a consultant.The importance of asking for feedback to become a more effective expert and leader.How to help your team navigate difficult conversations and create space to build trust.Learn more and access the resources mentioned in the show HEREResources Mentioned:Website: https://www.innovativehrresources.comLinkedIn: https://www.linkedin.com/in/innovativehrresourcesFor more leadership tips, don't forget to subscribe to She Leads Now on Spotify or Apple podcasts.Discover Your Values!The Personal Values Assessment is a simple survey that takes just a few minutes of your time and provides a wealth of information about why you do what you do. Who you are, what you hold dear, what upsets you, and what underlies your decisions, are all connected to your personal values. Results are sent to you via email with insights and analysis into Your Values & what they mean.About SabineWith a human-centered approach to leadership development, Sabine has been a Business Partner and Leadership Strategist for over 15 years, supporting emerging and seasoned leaders in growing their confidence, teams, and impact. Sabine is also the Author of Transformed, The Journey to Becoming, and Founder of SHE Leads Network, a professional development community for ambitious, impact-driven women in leadership, focused on transforming the way women work, lead, and do business together.Connect With Sabine!Website - https://www.sabinegedeon.comLinkedIn - https://www.linkedin.com/in/sabinegedeon

On episode 25 of the Ori Spotlight Podcast, Jason C. Foster is joined by Philip Vanek, CTO at Gamma Biosciences as they explore how the industry is evolving in a digitally connected world. Gamma Biosciences is a life sciences innovator focused on bioprocessing tools and technologies for the development and production of advanced therapies, including vaccines, biologics and cell and gene therapies. Philip is an entrepreneurial and strategic international business leader. Prior to Gamma Biosciences, he directed strategy and portfolio growth at GE Healthcare's Cell and Gene Therapy business unit. He has also held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza, and is currently a Board Member of CCRM in Toronto Canada and the ARM Foundation. Philip joined Jason to discuss the role of digital within the cell and gene therapy industry, overcoming manufacturing challenges to meet the demand for therapies, and how industry partnerships and collaboration can increase the momentum of progress. Learn more about Philip Vanek: https://www.linkedin.com/in/vanekphil/

Dom, who is the Founder and CEO DotConnect, where they find exceptional people for high-achieving companies. DotConnect has a team of 85 employees and has recruited for leading organizations such as the National Football League (NFL), Snapchat, Samsung Next, and Zendesk. Dom graduated early from high school and immediately started her recruitment career at the age of 17 after a neighbor got her an opportunity to work in the HR department of their organization. She went on to work for companies such as Life Technologies and BlackBerry as a senior recruiter for 10+ years before starting DotConnect. Dom is also the founder of Path Connect, a 12-week program that teaches recruiters how to better understand organizational charts and what it takes to source and vet top talent for tech organizations. Social Media Links: Website: https://www.dotconnectllc.com/ Instagram: https://www.instagram.com/wearedotconnect/ LinkedIn: https://www.linkedin.com/company/dotconnect/

In this episode of the Thoughtful Entrepreneur, your host Josh Elledge speaks with the Founder and Chief Conscious Connector of https://dotconnectllc.com/ (DotConnect), Dom Farnan.  DotConnect is a global talent advisory business that scouts and hires talent for technology businesses in the United States. DotConnect has a team of around 100 employees globally and has been around since 2019. Dom explains that DotConnect's growth can be attributed to many areas. Dotconnect doesn't work only with technology companies, they also have a big consumer products client that they work with now. They also have longer-term clients that are based on monthly retainers. Dom explains ghosting, not creating an optimized experience for hiring, and not understanding the talent or their values is some of the negative feedback that the recruiting space has received. The manner in which a leader comes off to their employees is what sets the stage for the work culture. Dom explains she had to do some self-reflection and work to create a better environment for her employees and that is how DotConnect has been able to grow so rapidly over the years.  Dom explains that DotConnect has grown from delivering against its promise and through referrals. The value of ownership and delivery is important to DotConnect as they are able to prove their worth and obtain or retain clients this way. Luckily the staffing climate today is much different than in April 2020. Dom advises that companies that are laying employees off the need to focus on key hiring. The ideal clientele for DotConnect would be a 50+ employee strong business that is building out the entirety of its organization at any level.     Key Points from the Episode: The impact DotConnect has on the world  How DotConnect is growing faster than other companies Recruiting Industry  How Dom's personal growth improved her business Personal life versus work life How to grow in a tactful way The state of staffing today  Ideal clientele for DotConnect    About Dom Farnan: Dom Farnan is the Founder and CEO DotConnect, where they find exceptional people for high-achieving companies. DotConnect has a team of 85 employees and has recruited from leading organizations such as the National Football League (NFL), Snapchat, Samsung Next, and Zendesk. Dom graduated early from high school and immediately started her recruitment career at the age of 17 after a neighbor got her an opportunity to work in the HR department of their organization. She went on to work for companies such as Life Technologies and BlackBerry as a senior recruiter for 10+ years before starting DotConnect. Dom is also the founder of Path Connect, a 12-week program that teaches recruiters how to better understand organizational charts and what it takes to source and vet top talent for tech organizations. Want to learn more? Check out the DotConnect website at https://dotconnectllc.com/ (https://dotconnectllc.com/) Check out DotConnect on LinkedIn at https://www.linkedin.com/company/dotconnect/ (https://www.linkedin.com/company/dotconnect/) Check out Dom Farnan on LinkedIn at https://www.linkedin.com/in/dom-farnan/ (https://www.linkedin.com/in/dom-farnan/) Don't forget to subscribe to The Thoughtful Entrepreneur and thank you for listening. Tune in next time! More from UpMyInfluence: ️  We are actively booking guests for our The Thoughtful Entrepreneur.https://upmyinfluence.com/guest ( Schedule HERE). Are you a 6-figure consultant? I've got high-level intros for you.https://upmyinfluence.com/b2b ( Learn more here). What is your #1 Lead Generation BLOCKER? http://upmyinfluence.com/quiz (Take my free quiz here).

Dr. Bob Nelson is considered the leading advocate for employee recognition and engagement worldwide. He has sold over 5 million books on those topics, including 1501 Ways to Reward Employees, The 1001 Rewards & Recognition Fieldbook, 1001 Ways to Energize Employees, The Management Bible, 1001 Ways to Engage Employees, and his latest book: Work Made Fun Gets Done!: Easy Ways to Boost Energy, Morale, and Results.   Dr. Bob has been featured extensively in the national and international media including The New York Times, The Wall Street Journal, CNN, CBS 60 Minutes, MSNBC, ABC, PBS and NPR about how best to motivate today's employees. He has presented on six continents and worked with 80 percent of the Fortune 500 companies.   Mario Tamayo has 30+ years of experience in maximizing human performance and organization development, and has been an advocate of promoting company cultures of enjoyable employment and recognition—demonstrating that “work made fun does, in fact, get done.” Mario is a principal with Tamayo Group Inc. (www.tamayogroup.com), a Cardiff-by-the-Sea, California–based leadership consulting firm. He coaches, writes extensively, and speaks and leads workshops on management development, presentations skills, and personal and professional empowerment. He has been responsible for several successful performance and product improvement initiatives for organizations, including Amylin Pharmaceuticals, The Anthony Robbins Companies, Broadcom, The Ken Blanchard Companies, Life Technologies, L'Oreal, Mitchell, Nelson Motivation, Petco, ProSciento, and Viasat. Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3 (https://www.surveymonkey.com/r/3DXCFW3) CME credit is available for up to 3 years after the stated release date Contact CEOD@bmhcc.org if you have any questions about claiming credit.

Hannah Life Technologies, a startup for couples trying to conceive, announced today it has raised $5.15 million in pre-Series A funding led by Monk's Hill Ventures.

Conscious Leader Dom is the founder and CEO of DotConnect, a company dedicated to finding the best people for high-achieving companies. She has dedicated her life to recruitment and after many years of hard work, she found herself burnt out. She made a pivot and more recently she discovered the benefits of being more conscious - she became a conscious leader. Her company now has over 90 staff and helps many other companies and leaders reach higher levels of consciousness in the workplace too. This is her story, well worth a listen. Connect with Dom here. Guest Bio. Dom Farnan is the Founder and CEO DotConnect, where they find exceptional people for high-achieving companies. DotConnect has a team of 85 employees and has recruited for leading organizations such as the National Football League (NFL), Snapchat, Samsung Next, and Zendesk. Dom graduated early from high school and immediately started her recruitment career at the age of 17 after a neighbor got her an opportunity to work in the HR department of their organization. She went on to work for companies such as Life Technologies and BlackBerry as a senior recruiter for 10+ years before starting DotConnect. Dom is also the founder of Path Connect, a 12-week program that teaches recruiters how to better understand organizational charts and what it takes to source and vet top talent for tech organizations.

Dr. Philip Nitschke, MD, Ph.D. is a medical doctor, humanist and founder and director of the pro-euthanasia group Exit International (https://www.exitinternational.net/), a leading end-of-life rights advocacy and information non-profit. Dr. Nitschke has written extensively in the area of voluntary euthanasia and assisted suicide, including three books, including: Killing Me Softly: Voluntary Euthanasia and the Road to the Peaceful Pill, The Peaceful Pill eHandbook, and Damned if I Do. Dr. Nitschke holds a Ph.D. in applied physics from Flinders University and is a graduate of Sydney Medical School. He is a seven-time nominee for Australian of the Year and is the recipient of many awards including the Rainer Humanitarian Award and Australian Humanist of the Year. Dr. Nitschke successfully campaigned to have a legal euthanasia law passed in Australia's Northern Territory and assisted four people in ending their lives before the law (Rights of the Terminally Ill Act) was overturned by the federal government. He was the first doctor in the world to administer a legal, voluntary, lethal injection. Dr. Nitschke remains a strong advocate of dying with dignity, spending time lecturing on the topic, and developing innovative technology concepts, including several end-of-life machines, including the Deliverance Machine, CoGen and Destiny devices, and his most recent, the SARCO capsule (https://www.exitinternational.net/sarco/).

Many have labeled our guest today as a Talent Acquisition Visionary. Most recently he was recognized by CIO Views Magazine as one of the most influential leaders in the Talent Acquisition industry in 2022.I'm referring to Mr. Doug Fauth, the Sr Director of Global Talent Acquisition & Development at Microvention.MicroVention, founded in 1997, has pioneered the development of catheter-based, minimally invasive, neuroendovascular technologies. Doug joined the company in 2016 after working for companies like Ernst & Young, Broadcom Corporation, Activision-Blizzard, Life Technologies, and Southern California Edison (SCE).At the start of his career, which now spans over 25+ years, Doug worked in a College & University setting where he was involved in career counseling and bringing companies on-campus to interview and hire current students, later transitioning to internal talent acquisition for organizations.Some highlights of what we covered:-Rising above the noise to get a company's message in front of talent and have it make them take action-Doug's philosophy on Talent Branding and why it's so different from most-Leveraging job postings as valued real-estate and breaking away from worn-out ways of writing them that don't work anymore-An innovative way of communicating with your employees-Doug's take on Employee Value Propositions and how to create one so that candidates will take note and want to speak with you!...and so much more

Jakrey is a strategic and analytical leader who thrives in challenging and changing environments with a customer-first-focused approach. He excels at identifying business needs and opportunities to create innovative, valuable and transformative products. Jakrey is also a product engineer and product manager specializing in AI and immersive technology.Jakrey has a biomedical engineering background and has worked in different biotech companies over the last ten years. He started his career as an assistant engineer focused on cellular systems and metabolic pathways analysis. He wanted to be a doctor, but he got a son at a young age which changed his plans a little bit, but he ended up graduating with a master's degree in biomedical engineering. He then joined Life Technologies company and later Thermal Fishers Scientific, which has provided systems for more than half of COVID-19 tests. They are also a major provider of vaccines and PTEs related to the treatment of COVID 19. Segmented timestamps:[02:02] - About Jakrey and what he does in the biotech space [08:20] - Jakrey shares about the time when he was faced with a nearly impossible goal and how he embraced that challenge[15:18] - About Web 3.0 technology and what Jakrey is excited about for the future [22:17] Jakrey's favorite business model that he came across recently ‘selling physical products with an additional asset.” [24:52] Using utility and consumer-based AI to train other people and increase productivity  [28:24] Humanistic AI, and its intent in enhancing inclusivity and inclusivity while avoiding detrimental consequences [30:16] - Some of the things that we should be grateful for and alarmed about when using AI  [36:42] - Happiness index creative expression and ways to optimize AI objective function toward self-reflection and empathy[39:09] - The future of micro-dosing in optimizing emotional states through external influences  [42:15] - Jakrey's practical decision-making framework that he has found very useful when approaching hard decisions Notable Quotes:“If you want to succeed, you have to do it differently.” ~ Jakrey Myers.“AI is meant to help and benefit us and not to detriment us, but some of our business objectives drive the wrong outcome.” ~ Jakrey Myers."AI doesn't necessarily know what is ‘true or false,' and what is ‘good or bad,' it's defined by objective of the function." ~ Jakrey Myers.“All big goals are built on actions, and actions are built from decisions.” Noah ScottUSEFUL LINKS: Reach Jakrey at:Website: http://jakrey.com/LinkedIn: https://www.linkedin.com/in/jakreymyers/Get more from The Big Possible show:Website: https://www.thebigpossible.com   RSVP for our next epic retreat here Follow us on social: @follownoah @thebigpossible

#biotech #roswellbiotech #moleculartech Paul Mola is the Chief Executive Officer and President of Roswell Biotechnologies, Inc., and a member of the company's board of directors. He founded Roswell in 2014, bringing more than 20 years of life science industry leadership and executive experience to the company. Previously, Mr. Mola was Head of Global Solutions at Human Longevity, Inc., working with genome sequencing pioneer Craig Venter to establish international precision medicine partnerships. Prior to that, he spent over a decade at Life Technologies / Applied Biosystems (now part of ThermoFisher Scientific), the global leader in life science tools, and the historical market leader in DNA sequencing technology, where he was President of the Enterprise Genomic Solutions Business Unit and Head of Strategy and Chief of Staff for the Genetic Systems Division. In these roles, he managed strategy and international, large-scale business engagements for the entire DNA Sequencing Technology portfolio. Mr. Mola received the Life Technologies' “Game Changer” award, the company's highest honor for work that transforms the company, for his accomplishments which included establishing the national genome sequencing program for the government of Saudi Arabia, driving the acquisition of the Ion Torrent sequencing platform, leading the commercialization of the SOliD sequencing platform, and developing the business strategy for the Genia sequencing platform (later acquired by Roche). Earlier in his career, Mr. Mola served in product development, sales, and marketing roles at Roche. He holds a post-graduate degree in Biotechnology and Business. https://www.linkedin.com/in/paul-mola https://twitter.com/paul_mola_ https://www.roswellbiotech.com/ Kindly Subscribe to CHANGE- I M POSSIBLE youtube channel www.youtube.com/ctipodcast

Every day we make decisions. Some are as simple as deciding when to leave for work in order to beat traffic or what to eat for breakfast. Others bear much greater importance, such as what new products to launch or what new markets to tackle. Analytics plays an important role in helping your business make these decisions in a smarter, more data-driven way.“The purpose of analytics is to help us make decisions, is to create decision-making capabilities across the company. The next step was to find out what those decisions are that we would need to make? When I say decisions, these are not like once in a quarter, boardroom decisions. I'm talking about everyday decisions that many of our colleagues make every single day.”Vijay Kotu is the SVP of Data and Analytics for ServiceNow, a company that is helping enterprises manage digital workflows. In this episode of the Data Chief, Vijay discusses how he is building a high-growth “mathematical enterprise” where frontline workers are empowered to make smarter business decisions with data and AI. He also speaks about the impact of ecosystems, the need for businesses to have a holistic view of their data in order to create positive outcomes, and why being intentional about analytics use cases is absolutely essential. Key Takeaways:Don't underestimate the impact of micro-decisions: We all want to be more data-driven, but don't fall into the trap of thinking that data and analytics can only be applied to once-a-quarter, boardroom-level decisions. Enabling frontline employees to be more data-driven in their everyday work is a hugely powerful way to make a positive impact across your entire business.Evaluate how data can improve workflows: The holy grail of analytics is converting insights to action. One of the most effective ways to do this is by automating workflows whenever and wherever possible. With automation, you help everyone in the business be more efficient without adding any extra work or manual decision-making.Data becomes exponentially more powerful when it's connected: Having all of your proprietary data in one place is a great way to start your data journey but it becomes exponentially more valuable when you connect it to outside data sources. Bringing together multiple sources of data gives you even richer insights about your customers, employees, and products.Data serves the business: At the end of the day, your data goals should align with that of businesses. Data and analytics professionals must remember that data is there to serve sales, marketing, product, IT, etc. into making better decisions for the business. They are the ones running the functions and the data and analytics teams are the backbone of that. Therefore, data teams should be designing products with that in mind.Key Quotes“The purpose of analytics is to help us make decisions, is to create decision-making capabilities across the company. The next step was to find out what those decisions are that we would need to make? When I say decisions, these are not like once in a quarter, boardroom decisions. I'm talking about everyday decisions that many of our colleagues make every single day.”“Data just in one place, it's less valuable. But when you connect it with other data points that you have, it becomes even more valuable.”“What are you going to do with those insights? That would be the actions. If these insights are helping you make a decision, how do we actually put that decision in action is closing the loop. That has been the Holy Grail of analytics. Rather than stopping at insights, you're closing the loop on helping people do that action here.”“The things that matter the most for our customers right now is a prioritization decision, and doing really well in those areas will help us reach further in our goal.”Bio:Vijay Kotu is Senior Vice President of Analytics at ServiceNow. He leads the implementation of large-scale data platforms and services to support the company's enterprise business. He has led analytics organizations for over a decade with focus on data strategy, business intelligence, machine learning, experimentation, engineering, enterprise adoption, and building analytics talent. Prior to joining ServiceNow, he was Vice President of Analytics at Yahoo. He worked at Life Technologies and Adteractive where he led marketing analytics, created algorithms to optimize online purchasing behavior, and developed data platforms to manage marketing campaigns. He is a member of the Association of Computing Machinery and a member of the Advisory Board at RapidMiner.To hear more about ServiceNow, check out their podcast.--The Data Chief is presented by our friends at ThoughtSpot. Searching through your company's data for insights doesn't have to be complicated. With ThoughtSpot, anyone in your organization can easily answer their own data questions, find the facts, and make better, faster decisions. Learn more at thoughtspot.com. 

Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. He is a leader in the field of functional genomics and proteomics. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and currently carries out a variety of projects in the areas of genomics and proteomics both in yeast and humans. These include the large-scale analysis of proteins using protein microarrays and the global mapping of the binding sites of chromosomal proteins. His laboratory built the first proteome chip for any organism and the first high resolution tiling array for the entire human genome.He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of big data and implementing it into healthcare.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

With over 30 years of IT experience, Howard Miller is the current CIO at UCLA Anderson School of Management. His previous roles included acting CIO and CISO at the Columbia Business School and the IT Director of Life Technologies. Having started as an entry-level programmer, Howard has been through it all and has made it to the top of the IT rung. Howard has expertise in the design, development, and deployment of strategy and policy and has succeeded in building business processes from scratch.In this episode, Howard talks about the importance of SaaS governance and its implementation in organizations, along with some day-to-day examples. 

Amy DuRoss, CEO and Co-founder of Vineti, a committed patient advocate, is blazing a trail to orchestrate the supply chain to democratize treatments focused on personalized medicines. This is not her first moon shot to give power to patients. Before co-founding Vineti, Amy focused on healthcare new business creation for GE Ventures/ healthymagination. Prior to GE, Amy was Chief Business Officer at Navigenics, a genomics company sold to Life Technologies in 2012. She was co-founder and Executive Director of Proposition 71, California's $3B stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Amy holds an MBA and MA/BA from Stanford University. She was named a 2016 Health Innovator Fellow by the Aspen Institute. Connect with Amy DuRoss:  https://www.linkedin.com/in/amy-duross-695b743/ Connect with Robby Allen: https://www.linkedin.com/in/robbyallen Connect with Poya Osgouei: https://www.linkedin.com/in/poyaosgouei/                                    This week's episode was supported by Oracle NetSuite (sign up for a personalized product tour at www.netsuite.com/scale), Indeed (get a $75 credit for your job post at www.indeed.com/scale) and Bambee (Get your HR Audit for free at Bambee.com/uncharted or Bambee.com/scale) --- Support this podcast: https://anchor.fm/uncharted1/support

This Podcast episode cannot get any closer to what personalized medicine is really about. Welcome Dr. Dan Rhodes, the founder and CEO of Strata Oncology, a leading precision oncology company leveraging state-of-the art genomics tools for more efficient cancer diagnostics and treatment. Dan is a bioinformatician by training and spent his entire career applying genomics to solving complex problems in oncology. Dan founded two very successful startups in this field and also has gathered vast experience working as a VP of Oncology Strategy at large corporations (Life Technologies and Thermo Fisher). This interview is full of deep insights on the state of genomic testing in cancer treatment and reflections on the future of precision oncology.◦ Tune into this episode to learn more about:◦ Dan's journey from a PhD student to a serial biotech entrepreneur◦ Differences between working in a small start-up vs large organizations◦ Strata's mission to determine best possible treatment for each cancer patient◦ Role of RNAseq in precision oncology◦ Approaches for highly-sensitive NGS of solid tumors◦ Paradigm shift in clinical trials for personalized therapeutics◦ Reimbursement landscape in cancer genomics◦ Potential of asymptomatic NGS screening in oncology◦ Dan's vision for the future of precision oncologyMake sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com

Support the Show. Get the NEW AudioBook! AudioBook: Audible| Kobo| Authors Direct | Google Play | Apple SummaryHey everyone. I'm trying something new based on your feedback. Stay turned to the end of the interview where I'll give you some actionable insights that I learned from my guest. These insights are also in the show notes. As always, thanks for listening. Now on to my guest today, Dan Salehi, a patent lawyer who shares his observations about business growth, particularly about the new phenomenon of SPACs.  Dan studied engineering in college but decided to switch to law, entering the world of patent law. He became curious about the big picture of why businesses choose to build what they built. He gradually transitioned to helping corporations close deals, but patent law remains an integral part of what he does. Dan explains that he never wanted to be one-dimensional and was always interested in understanding the bigger picture. In this episode Dan provides his insider view of SPACs - Special Purpose Acquisition Companies - which are an alternative to the traditional route of going public. He also talks about why patents are an important part of building a business when done correctly.  Some of the questions Dan addresses are:  What are SPACs? Who are the key players and how does it work? When should a company consider going that route? Why might now be the optimal time to explore it?   What purpose does a patent serve in building a business? When and how should you patent an idea? How do patents play a role in business growth?  You should also know that Dan and I both worked at Ion Torrent and then Life Technologies when Ion got bought by them. To all my Ion friends, I hope you enjoy this walk down memory lane. Now let's get better together. Actionable InsightsDan provides some advice for entrepreneurs who are ready to take the next steps in growing and scaling their businesses: First, prepare your “exit” strategy - the way you will move out of the startup phase.  Protect your ideas with patents and trademarks. Spend your money wisely and appropriately. You don't have to patent everything but should have a “picket fence” approach where you patent the broadist ideas you can. Narrow down your priorities; prepare a pitch deck and start fundraising. Ensure your ideas are protected through patents since investors will ask.  Prepare for your exit by exploring opportunities like going to an IPO or SPAC. You can also look at getting acquired. Links to Explore Further Dan Salehi on LinkedIn Spectrum IP Law Group Keep In TouchBook or Blog or Twitter or LinkedIn or JSYPR or Story Funnel Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to Reimagining Company Culture, a series discussing emerging trends and priorities shaping the future of workplace culture and employee wellbeing. We highlight thought leaders who are constantly evolving their strategy and can provide insight to folks about how to address new business challenges.  AllVoices is on a mission to create safe, happy, and healthy workplaces for all, and we're excited to learn from experts who share our mission.In this episode of Reimagining Company Culture we're chatting with Dan Spaulding, Chief People Officer of Zillow Group.  Dan leads Zillow Group's people operations, focusing on creating solutions and programs to inspire their talented employees nationwide.As Chief People Officer of Zillow Group, Dan leads the company's people operations, including human resources, recruiting, equity & belonging, learning & development, and facilities teams. He focuses on creating solutions and programs to attract, engage, develop and inspire Zillow Group's talented employees across its offices nationwide.Prior to joining Zillow Group, Dan was vice president of U.S. Stores and Operations and Human Resources for Starbucks, where his team drove support and strategy for over 8,000 stores and 140,000 employees nationwide. Before Starbucks, Dan held various leadership roles on human resources teams at Life Technologies and Dell, Inc.Dan earned a Bachelor of Arts in Political Science and History from Knox College and currently serves on its Board of Trustees. He also earned a Master of Science in Human Resources and Industrial and Labor Relations from the University of Illinois.About AllVoicesIn today's workforce, people often don't feel empowered to speak up and voice their opinions about workplace issues, including harassment, bias, and other culture issues. This prevents company leadership from making necessary changes, and prevents people from feeling fulfilled, recognized, and included at work. At AllVoices, we want to change that by providing a completely safe, anonymous way for people to report issues directly to company leaders. This allows company leadership real transparency into what's happening in their companies—and the motivation to address issues quickly. Our goal is to help create safer, more inclusive companies.To learn more about AllVoices visit us at www.allvoices.co!

Euan Rellie is Co-Founder and Senior Managing Director of BDA, based in New York. He is also President of BDA Advisors Inc, the firm's SEC/FINRA registered broker-dealer. Since founding BDA in 1996, he has lived in New York and London, and Singapore, and has worked in China, Taiwan, Korea, Japan, India and across the Middle East. 1990-1996, he worked for Schroders, the UK investment bank now part of Citigroup, in New York, London and Singapore. He was Head of SE Asia Execution for Schroders Asia-Pacific Regional Advisory Group. His clients include AgFeed, Ardian, Bain Capital, CITIC Capital, Dainippon Ink & Chemical, DuPont, Ecolab, Flex, Hanjin, Happy Socks, ICICI, Intel, Investcorp, Kraft Foods, Life Technologies, Lubrizol, Materion, Nalco, One Equity Partners, OpenGate Capital, Pfizer, Philip Morris, Platinum Equity, Sara Lee, Sigma-Aldrich, Tenneco, Terex, ThomsonReuters, Wockhardt and Yucaipa. He was named Dealmaker of the Year in 2016 and 2012 (by The M&A Advisor), 2014 North American Investment Banker of the Year, and one of the Top 50 Global M&A Dealmakers (by The Global M&A Network). He was educated at Eton and Trinity College, Cambridge. Charlie Maynard is Co-Founder and Senior Managing Director of BDA. Since founding BDA in 1996, Charlie has been based in Singapore, Tokyo, New York, Beijing, and now London. Charlie was based in Tokyo from 2002 to 2005 and established BDA's office there and in Seoul. He has advised on a number of successful transactions throughout the region. Charlie advised Navis Capital in China's largest control exit in 2014 by a private equity group, the sale of Trio to Weir plc. In 2015 he has advised Cosma (a Magna International subsidiary) on its acquisition of Chongqing Xingqiao and Cristal on its acquisition of Jiangxi Tikon. Prior to BDA, he worked for the Jardine Matheson Group in Hong Kong and Singapore. In 2011, he was named by M&A Advisor as one of their “40 Under 40” global M&A professionals. Charlie was educated at Oxford University (MA Hons, Geography). BDA Partners is the global investment banking advisor for Asia. BDA is a premium provider of Asia-related advice to sophisticated clients globally, with over 20 years' experience advising on cross-border M&A, capital raising, and financial restructuring. BDA has strategic partnerships with William Blair, a premier global investment banking business, and the Development Bank of Japan (DBJ), a Japanese government owned bank with total assets of US$150bn.

Dr. Stephan is an industry veteran who is considered one of the fathers of the field of precision medicine, having trained with the leadership of the Human Genome Project at the NIH and then going on to lead discovery research at the Translational Genomics Research Institute and serve as professor and chairman of the Department of Human Genetics at the University of Pittsburgh. Stephan has identified the molecular basis of dozens of genetic diseases and published extensively in journals such as Science, the New England Journal of Medicine, Nature Genetics, PNAS and Cell. In parallel, Dr. Stephan has founded or co-founded 14 biotechnology companies and has advised an additional 12 companies. These companies are backed by top-tier investors such as Sequoia Capital, KPCB, Thiel Capital, and Khosla Ventures as well as corporate partners such as Life Technologies, Pfizer, and Mayo Clinic. Dr. Stephan received his Ph.D. from the University of Pittsburgh and his B.S. from Carnegie Mellon University.

William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director, President & CEO, moving multiple programs into clinical testing, completing several acquisitions and eventually taking the company public. Prior to joining Altimmune, Bill spent six years with GenVec, Inc. (acquired by Intrexon) with increasing responsibilities, which included a role as Head of Business Development. Bill has raised more than $300 million through private, public and non-dilutive financings. Bill brings a breadth of experiences in a variety of positions within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc. (acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Bill received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.

What does it take to commence a successful biotechnology start-up? What risks are involved as a private equity investor? How can one manage and offset the risks of cashflow and company control vis-à-vis founders possessing controlling shareholdings? Hear from Dr William H. Janeway, a private equity giant from Warburg Pincus and University of Cambridge, Faculty of Economics lecturer. This is a recording from a live webinar event that took place on 12th June 2020. Content: During this webinar, Bill discussed the economics of innovation as illustrated by the founding of Life Technologies and resolution of the ‘Biotechnology Paradox’. Bill delved into the risks associated with investing as a private equity investor in this industry and the substantial growth in the number of pharmaceutical and biotechnology IPOs in the US. Format: Opening remarks were provided by Bill. Pre-submitted questions from our audience were then asked and further questions submitted via the online platform ‘Menti’ were welcomed on the topic. This event was organised by CUTEC and CUVCPE societies as part of the ongoing ‘CUTalks by CUTEC’ podcast series. The hosts for the webinar were Shreya Singhal and Shelby Newsad. To find other podcast episodes, visit here: https://cutec.io/cutalks. Follow us @CUTEC, #CUTalks and @CUVCPE on LinkedIn, Twitter and Facebook to find out about future events and podcast episodes.

Kevin McKernan believes there are too many scientists paid from tax money, and that the free market would have handled the Coronavirus crisis much more precisely if the government had not intervened.  His controversial ideas are explained with detail and a level of understanding that is simply amazing.  I felt genuinely uncomfortable as he approached topics that are controversial, but his nuance made the conversation particularly compelling and interesting.Kevin is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature.Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years.  In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters.  When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening.Kevin can be found on Twitter: @Kevin_McKernanVance can be found on Twitter: @Vance CroweWe spoke about videos on Kevin's YouTube channel:We also discussed @EricRWeinstein@nntaleb

On episode 7 of Superpowers, Bill and Chris have a motivating discussion with Matt Capizzi, the CEO and co-founder of Zenrez, a software startup that offers innovative, data-powered business solutions to yoga studios. Matt’s superpower is his irrational confidence. A charismatic and confident entrepreneur, Matt’s career in product management started in the biotech industry. After working his way up to product manager at Life Technologies, Matt began to develop his superpower. As Matt says, he realized that “the biggest asset I have… is just the ability to handle pressure. The ability to be comfortable in the uncomfortable.” The idea for Zenrez came to Matt while taking high-level supply chain and operations management classes for his MBA at Carnegie Mellon. “I thought, I’m never going to use this stuff but it’s cool that I know that it exists now. And then I started getting into yoga…” Matt saw a massive opportunity to implement demand-based pricing in the yoga industry. He observed the success of Uber’s pricing model. “Once I saw consumers accept that volatility in price, then I was like – this is going to happen in every single industry,” he told Bill and Chris. Matt started Zenrez with his older brother and a talented engineer he befriended at CMU. They developed a software platform that yoga studios could use to implement demand-based pricing and growth marketing automation. “I spent the next summer doing customer development,” Matt told the hosts. He and his brother started taking yoga classes, “we’d look on the schedule [to see] when the owners would teach, and we would buy an intro pack.” They would pitch their application in person, and thanks to Matt’s irrational confidence, Zenrez grew. Today more than 1,000 studios use Zenrez.

Peter Christey, PhD, CEO and Co-Founder of GALT (General Automation Lab Technologies), on the web at (galt-inc.com), discusses his work in microbial cultivation. Christey has over 20-years experience commercializing research instruments for a number of complex applications. Prior to his launch of GALT, Christey helmed the DNA Sequencing Business Unit and DNA forensic product line for Life Technologies. Christey discusses his background and how his focus in microbial cultivation in a laboratory setting drove him to develop microbes for use in multiple areas. He explains proteomics applications, microbial diversity, and his company's platform—detailing how they work to get a pure isolate (a culture of living microorganisms) into culture in the lab in order to study biochemistry and physiology. They strive, primarily, to deliver pure, living isolates to researchers and product developers. Utilizing the GALT technology, entire populations of microbes can be screened efficiently and quickly for low-abundance species or perhaps strains that demonstrate selected characteristics. Estimations have surmised that there are approximately one-trillion microbial species on our planet, but remarkably, less than one percent of the known species have actually been cultured. So many species remain unexplored and we just don't have any information on them. Christey discusses how isolates are understood, and how scientists can test them. He discusses the microbiome, and the growth media that they use in their research. And he provides extensive information on how bacteria grow, and the requirements that are necessary, including a discussion of symbiotic relationships.

On this episode of The Tatiana Show,  Tatiana and Josh speak with our returning guest, Kevin McKernan, about how he combatted hacked servers and secured his Medicinal Cannabis Genomics data using encrypted blockchain technology. These so-called “Honey Pot” data servers were trusted until they implemented their premeditated plan to steal their customers data in order to use it for competitive advantage. We also hear more about the newest science behind Cannabis Genetics - such as a brewing technique that integrates cannabis within a yeast strain. Stay tuned to learn the surprising bit about how psychoactive compounds are made - not grown organically. McKernan is an expert in the field of Cannabis Genomics and we are excited to share his amazing journey through one of the fastest-growing industries with our listeners. As always, thank you to our sponsors Vaultoro and SALT Lending.  Cheers! About the Guests: Kevin is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and was Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLiD sequencing technology. Integral to the SOLiD R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 Journal covers from Science Translational Medicine to Nature. Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years.  In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until it was acquired by Beckman Coulter. Kevin also managed the R&D for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoy boating, skiing, and gardening.   If you like this content, please send a tip with BTC to: 1444meJi7YjgQGNg3U8Z6qYZFA5cgz4Gmj More Info:  MedicinalGenomics.com TatianaMoroz.com CryptoMediaHub.com Friends and Sponsors of the Show:  SaltLending.com/Tatiana Vaultoro.gold/tatiana Proof of Love Podcast *You have listened to the Tatiana Show.  This show may contain adult content, language, and humor and is intended for mature audiences.  If that’s not you, please stop listening. Nothing you hear on The Tatiana Show is intended as financial advice, legal advice, or really, anything other than entertainment.  Take everything you hear with a grain of salt. Oh, and if you’re hearing to us on an affiliate network, the ideas and views expressed on this show, are not necessarily of the those of the network you are listening on, or of any sponsors or any affiliate products you may hear about on the show.

Joseph DiGiovanni started his career in sales, beginning as a Sales Manager for Life Technologies in 1993 and then moving to LabCorps and Lycos. He then moved into higher positions in other organizations such as Senior Vice President and President. All of this led him to co-found TAPP Network in 2013. TAPP was created to leverage technology and content to educate audiences, foster healthy brand engagement, and promote positive behavior change, while generating measurable results. TAPP is a host-sponsor of WINPL.Connect with TAPP:• https://www.tappnetwork.com/ • • https://twitter.com/TappNetwork • • https://www.instagram.com/tappnetwork/ • • https://www.facebook.com/tappnetwork/ • • https://www.linkedin.com/company/tappnetwork/ •Connect with Luxe Podcast Production at luxepodcasts.com and on Instagram @luxepodcasts.

Mr. Ghazi Kashmolah is a 25+ year veteran with a variety of relevant experience across the Regulatory Affairs & Quality space. An immigrant from Iraq, Ghazi built up an impressive track record having held a variety of influential leadership roles with organizations such as Life Technologies, OSI Systems, and now DJO Global. Ghazi has significant consulting experience as well in the areas of both Operations and Supply Chain. Listen in as Ghazi shares fantastic insight to drive your career and your organization forward.

Highlights include: • Sequencing the cannabis genome • The process of submitting a project for funding from the Dash DAO • The banking crisis in the cannabis industry • Medical marijuana and CBD oil • Obstacles posed to the cannabis industry by the US government • Will the Trump administration legalize cannabis? • How blockchain can become part of popular culture • Reclaiming the mainstream narrative of bitcoin and blockchain technology • The recent Facebook purge and alternative social media platforms We’re moving to a new audio format! While I enjoy seeing the lovely faces of all my guests, we are trying some new things for The Tatiana Show. Audio-only enables me to work with less bandwidth while I’m recording shows on the road, and makes for easier editing. This means listeners will get more regular, top quality episodes! Thank you always to The Tatiana Show sponsors: Stamps.com, The Bitcoin CPA, CryptoCompare, and my marketing company, Crypto Media Hub. Kevin Mckernan kicks off this episode and treats us to his extraordinary range of knowledge and experiences from the cannabis and cryptocurrency spaces. Kevin has spent his career researching and developing various DNA sequencing technologies in both the research and clinical industries. He is the CSO and Founder of Medicinal Genomics. Kevin explains how he obtained funding for his cannabis genome sequencing project from the Dash DAO. For people who don’t know, Dash is a cryptocurrency that not only uses its fees to pay miners, like Bitcoin does, but also puts tokens from its fees into a treasury. People can then propose projects to Dash stakeholders and receive money from that fund. The Patent and Trade Office (PTO) has posed various obstacles to the cannabis industry, particularly through a controversial and overly broad patent issued in 2015, which Kevin helped to oppose. We also discuss the banking crisis in cannabis and in general how governments have stifled cannabis research and innovation for generations. Mckernan explains that “through prohibition, everyone started breeding for high THC, and that has come at the cost of all the other cannabinoids not being made” (20:23). There are rarer cannabinoids, with more therapeutic effects. Kevin and his team targeted one of those rarer strains to sequence for their Dash project. We also delve into some examples of diseases and ailments that can be aided by cannabis and CBD oils. At 24:00, Kevin treats us to a brief world history of cannabis, discussing how different strains originated in different parts of the world. The earliest cannabis was present 20 million years ago in the Hindu Kush mountain range. Ancient people grew hemp for its fibers, which were useful for making sails for their ships. Do you think the Trump administration will legalize marijuana? We discuss how new cannabis industries have affected the American economy and how Canada’s recent legalization of cannabis could force the Trump administration’s hand in U.S. policy-making (34:00). Kevin’s event is Cannmed, currently taking place at UCLA this week. Next we’re joined by Naomi Brockwell (37:30). Naomi is a film and television producer for John Stossel; she also hosts her own Youtube show on blockchain, bitcoin, and technology. Her newest project is a crypto thriller noir series called Hard Fork. She discovered the project through Steemit, where she connected with Doug Karr, an alumni of the Sundance festival, and Christopher James Baker (of the television series, Ozarks) as they were putting together this blockchain sci fi thriller. Like Kevin McKernan, they also received funding from the Dash DAO, and they’ve raised their first million dollars. The show is still in development. They will go into production and are hoping for a release at the end of 2019. Follow Naomi on social media (@NaomiBrockwell) or check out hardforkentertainment.io to stay updated. Naomi says of the Hard Fork series: “I wanted to get involved because all you hear about with crypto is the negative. ‘Oh it’s a bubble. Everyone in crypto is a loser.’ The mainstream media just talks about the drug dealers and money launderers and how they’re awful. But blockchain is the most empowering technology we’ve seen in the last hundred years. This is a way to decentralize trust. This is a way to completely revolutionize the traditional financial sector. Please do not discount this. Let’s talk about all the ways that this can change lives, how this can give people back more freedom, more financial autonomy. So I think getting in control of that narrative and creating a mainstream-audience-accessible series that actually looks at the way this can be a really empowering tech is what drew me to the project.” Cheers to that! Naomi came to cryptocurrency from a background in Austrian economics, in which economists like F.A. Hayek were eerily prescient about cryptocurrency. Speaking of economics, I’ll be seeing Naomi next on the Contra Cruise! Comment below if you’ll be there. Josh is missing out, but he’s helping with the Bitcoin Lightning Network Hack Day in New York. (56:00) Finally, we discuss Steemit, alternative social media, the recent Facebook purge of many libertarian pages and outlets, and how other activists have struggled with banning on various platforms. Naomi is a big fan of BitChute, an alternative to Youtube. If you’re interested in more on these topics, check out another recent episode of The Tatiana Show, in which I interviewed Bill Ottman of Minds.com and Matt Asher of BeforeTheBan.com. Thanks so much to my co-host Joshua Scigala, and our awesome guests! We hope you enjoy the episode! About the Guests: Kevin has spent his career researching and developing various DNA sequencing technologies in both the research and clinical industries. Additionally, Kevin has had a parallel interest in driving the tools used for personalized medicine into the world of cannabis medicine. Kevin believes the intersection of personalized medicine, genomics, blockchains and cannabis is one of the most exciting growth opportunities in our lifetime. Kevin is the CSO and Founder of Medicinal Genomics and has pioneered the genomics of cannabis and hemp to build a stronger scientific environment (Kannapedia.net) for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. Previously, Kevin was the CSO of Courtagen Life Sciences, Inc., and held the position of Vice President and Director of R&D of Life Technologies where he managed the development of Life Technologies next generation SOLID sequencing technology. Integral to the SOLID R&D process, Kevin oversaw over 100 research collaborations exploring the new biological frontiers with next generation sequencing and saw particular excitement and traction in human tumor sequencing. Kevin initiated an R&D project to investigate chemFET semiconductor based DNA sequencing and spearheaded a process to acquire the DNA sequencing  company Ion Torrent for $350M. These collaborations resulted in hundreds of publications and 7 journal covers from Science Translational Medicine to Nature. Kevin was the President and CSO of Agencourt Personal Genomics, a startup company he co-founded in 2005 to invent revolutionary sequencing technologies that dropped the cost of sequencing a human genome from $300M to $3,000; a 100,000-fold improvement in sequencing speed and cost in a few years. Kevin oversaw the growth and research of APG until it was sold to Applied BioSystems. In 2000, Kevin Co-Founded Agencourt Biosciences Corporation and acted as the CSO until 2005 where it was acquired by Beckman Coulter. From 1996 to 2000 Kevin managed the Research and Development for the Human Genome Project at Whitehead Institute/MIT resulting in several patents for nucleic acid purification. Kevin holds a B.S. in Biology from Emory University with a focus on cloning and expressing Norepinephrine Transporters. When not decoding DNA and unraveling the mysteries of cannabis medicine, Kevin enjoys boating, skiing, and gardening. Naomi Brockwell is a film and television producer, and host of the show "Bitcoin, Blockchain, and the Technologies of our Future". She is a producer for Stossel, a producer for the TV series HardFork, and formerly produced for Fox Business Network and Fox News Channel. Naomi is the co-founder of The Soho Forum, on the Advisory Council at the Mannkal Economic Education Foundation, and in 2017 was awarded Uber's "Young Libertarian of the Year" at the Friedman Conference. She has produced numerous award-winning feature films, including the 2015 feature documentary Bitcoin: The End of Money as We Know It (Best International Documentary, Anthem Film Festival; Winner of Special Jury Prize, Amsterdam Film Festival), Audition (Best documentary, Lone Star Film Festival) and the Lionsgate thriller, Subconscious. Check out her daily videos at Youtube.com/NaomiBrockwellTV If you like this content, please send a tip with BTC to: 1444meJi7YjgQGNg3U8Z6qYZFA5cgz4Gmj More Info: TatianaMoroz.com CryptoMediaHub.com Medicinalgenomics.com Cannmedevents.com Osf.io/7d968/ Bigbudsmag.com/will-jamaican-lion-save-the-cannabis-industry-from-patent-trolls/ Dashforcenews.com/dash-labs-exclusive-update-interview-with-tito-rios-on-data-collection-protocol/  Youtube.com/channel/UCD-8zwMuJMW_Rf9xw3SF4Ew Hardforkentertainment.io Youtube.com/NaomiBrockwellTV Friends and Sponsors of the Show: TheBitcoinCPA.com CryptoCompare.com Stamps.com

“As a leader, you’re the tip of the spear for change.” — Greg Lucier  One of the most successful CEOs in the U.S., Greg Lucier has led companies including General Electric, Life Technologies (now ThermoFisher Scientific) and NuVasive to success. However, what stands out most is how he’s handled the challenges he’s faced along the way. In this Takeover Tuesday episode, Dermot Buffini and Greg discuss success and leadership. Greg delves into his journey from the Philadelphia suburbs to Harvard Business School to his start at GE during the era of Jack Welch. He shares the three lessons he learned at GE, the biggest mistake he made during his transition to Life Technologies and the daily habits that keep him sharp and healthy. You’ll learn the five must-have characteristics of successful leaders, why self-awareness is vital to becoming an effective leader, and the one thing parents must instill in their children in order for them to thrive. Whether you’re currently leading a business, an aspiring leader or raising future leaders, you won’t want to miss this episode. Are you a Buffini Show Insider? What are you waiting for? Join today!   Inspirational quotes from today’s interview: “Culture is actually teamwork. If you have a great team, you can be in a room with white walls and no pictures and actually feel awesome.” — Greg Lucier “As a leader, you’re the tip of the spear for change.” — Greg Lucier “Visions are easy to come up with; achieving them is hard.” — Greg Lucier “The ability to understand abstract concepts will become critically important.” — Greg Lucier “Leaders have the don’t quit mentality because they believe they matter and if they pull themselves out, it’s not going to work.” — Greg Lucier “Our goal as elders is to create a world where kids leave their house and have a good launch. If nothing else, a good sense of self confidence. If parents aren’t thinking of that one thing to launch their kids, they’ve missed it all.” — Greg Lucier “Transitions are important in your career; but always make sure you walk out the front door.” — Greg Lucier   Mentioned in the episode: The Rise of Theodore Roosevelt by Edmund Morris   Connect with Brian Buffini http://www.brianbuffini.com Facebook: https://www.facebook.com/brianbuffini Twitter: https://twitter.com/brianbuffini Buffini Show Insiders: http://www.thebrianbuffinishow.com/insiders Love what you heard? Share it with your friends! http://bit.ly/BrianBuffiniShow Click here to buy our Podcast theme music, “The Cliffs of Moher” by Brogue Wave. http://www.broguewave.com http://www.facebook.com/broguewave

On February 22, 2017, the Supreme Court decided Life Technologies Corp. v. Promega Corp. Promega Corporation owned four patents for technology used in kits that can conduct genetic testing and was the exclusive licensee of a fifth patent. In 2010, Promega sued Life Technologies Corporation (LifeTech) for allegedly infringing on these patents. A jury found in favor of Promega but the district court nevertheless ruled for LifeTech, concluding that Promega had failed to present evidence sufficient to sustain the favorable jury verdict. The U.S. Court of Appeals for the Federal Circuit reversed that judgment, holding that the four Promega patents were ultimately invalid but agreeing that LifeTech had infringed the fifth patent and remanding to the district court for a determination of damages. In the course of its ruling, the Federal Circuit concluded that LifeTech’s supplying of a single, commodity component of a mulit-component invention had exposed LifeTech under federal law to damages liability on worldwide sales. -- The question before the Supreme Court was whether the Federal Circuit erred in holding that supplying a single, commodity component of a multi-component invention from the United States exposes a manufacturer to liability for worldwide sales. -- By a vote of 7-0, the Supreme Court reversed the judgment of the Federal Circuit and remanded the case. In an opinion by Justice Sotomayor, the Court held that the supply of a single component of a multicomponent invention for manufacture abroad does not give rise to liability under Section 271(f)(1) of the Patent Act, which prohibits the supply from the United States of "all or a substantial portion of the components of a patented invention" for combination abroad. Justice Sotomayor’s opinion was joined by Justices Kennedy, Ginsburg, Breyer, and Kagan. Justices Thomas and Alito joined the majority opinion as to all but Part II-C. Justice Alito filed an opinion concurring in part and concurring in the judgment, in which Justice Thomas joined. Chief Justice Roberts was recused. -- To discuss the case, we have Howard J. Klein who is Attorney at Law at Klein, O’Neill & Singh, LLP.

Life Technologies Corp. v. Promega Corp. | 12/06/16 | Docket #: 14-1538

For more than 25 years, Patricia has chosen the “road less traveled” in building her career, focused on breaking new ground in order to solve hard problems. She brings executive operating experience from both early stage and mature companies in the medical device, diagnostics, life science companies, including Life Technologies, T Cell Sciences and Sigma Aldrich Corporation.  She has brought multiple new products to market in the areas of HIV monitoring; cancer diagnostics, pharmaceutical drug discovery. Prior to founding ActualMeds , Patricia founded RedTail Solutions, a Software as a Service (SaaS) company serving middle-market manufacturers in the global supply chain. While serving as its CEO (2000-2008), she established a new revenue and business model in this segment and built a capital-efficient business that achieved profitability in 2007. Armed with lessons learned in the retail supply chain about the value chain of information, Pat has returned to healthcare at a time when interoperability is one of the keys to its transformation, and she expects ActualMeds to play a major role in it. Patricia holds a B.A. degree in Biology from Kenyon College, an M.S.  in Biochemistry and an M.B.A. from Case Western Reserve University. 00:00 Pat talks adherence and non-adherence.01:45 80% of the adherence problem is attributed to high-risk group and older adults--over 65, and multiple chronic issues.05:00 The complexity of being “adherent” vs. making sure that the patient is taking the right amount of medication that they need.09:00 The average amount of time that a doctor actually sees a patient during a visit is somewhere around 7-9 minutes.11:25 Pat explains ActualMeds, and what the company is doing to improve patient adherence, point of care, and overall a patient's health.12:30 A typical scenario of what using ActualMeds looks like.15:00 Surescripts and how this company's data sets helps ActualMeds and improving patient adherence.16:30 The problem with EHRs and too much data.18:30 How ActualMeds is automating the need to call and verify patient medications with pharmacists.20:00 The ways in which users can access the ActualMeds systems.22:00 How ActualMeds provides information for doctors so that they can make the right calls to ensure that patients are not doubling up or taking unnecessary medications.23:20 Who utilizes ActualMeds the most.25:00 How do hospitals and large health systems reconcile with patients post-acute care?26:30 Medication management is now considered to be a best-practice.27:00 How and when ActualMeds was founded.28:50 The huge gap in patient medication reconciliation.30:10 Medication Reconciliation is part of wellness visits, and how it is becoming more and more a best-practice requirement.34:00 If you want to learn more about Actual Meds you can visit their website at http://www.adheretx.com/.

Dr. Michael Snyder is the Stanford Ascherman Professor and Chair of the Department of Genetics at Stanford University, as well as the Director of the Stanford Center for Genomics and Personalized Medicine. Mike is also a co-founder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies. He received his PhD from the California Institute of Technology and completed postdoctoral training at Stanford University. He served on the faculty at Yale University for over 20 years before joining the faculty at Stanford. Mike has received many awards and honors during his career, including the Burroughs Wellcome Scholar Award, the Connecticut Medal of Science, and the Pioneer Award from the Human Proteome Organization. Mike is here with us today to tell us about his journey through life and science.

Managing Editor, Ranjini Prithviraj, highlights content from the December 2013 issue of ACS Synthetic Biology. Federico Katzen from Life Technologies discusses the splitting of the E. coli chromosome into two linear chromosomes.

Leadership comes from many sources and angles. Grassroot movements based on passion is one of those sources. Today we talk about grassroots organizing for scientists with Mary Canady.Mary Canady, Ph.D., is the founder of Comprendia, a firm specializing in helping biotechnology and life science companies grow through the creation, commercialization, and communication of value. Dr. Canady was a research scientist for ten years and worked for eight years in biotechnology marketing and business development at Life Technologies, EMD Millipore, and startup companies. In 2008, she founded Comprendia, leveraging social media to build an extensive network of 20,000 life science and biotechnology professionals. Comprendia relies on this social media expertise in working with more than 15 life science companies to help them engage with their customers, strengthen their online brand, and ultimately to thrive in the new media economy.

091112 Andrews

Jennifer Quint, Thorax’s Journal Club editor, talks to David Jablons, University of California San Francisco, and consultant for Life Technologies, about his assay to predict survival in resected non-squamous, non-small-cell lung cancer.See also:http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2961941-7/abstract

Brenda Maribel Corado, a 32 year old mother was walking her 21 day old baby Angela to a doctor's appointment when a couple of women approached her on the street, taking Angela from her mother's arms. Angela had just been kidnapped! Listen to the story as Brenda explained it to Life Technologies employees today when she expressed a heartfelt thank you to the makers of the DNA analysis human identification product that reunited her with her daughter.  

Brenda Maribel Corado, a 32 year old mother was walking her 21 day old baby Angela to a doctor's appointment when a couple of women approached her on the street, taking Angela from her mother's arms. Angela had just been kidnapped! Listen to the story as Brenda explained it to Life Technologies employees today when she expressed a heartfelt thank you to the makers of the DNA analysis human identification product that reunited her with her daughter.  

Life Technologies has just released a free webinar. Ambion scientists Emily Zeringer and Marie Gonzalez present the background, methods and what to expect when extracting nucleic acids from FFPE tissue samples. Watch the FFPE webinar now.

Life Technologies has just released a free webinar. Ambion scientists Emily Zeringer and Marie Gonzalez present the background, methods and what to expect when extracting nucleic acids from FFPE tissue samples. Watch the FFPE webinar now.

A radio interview with Dr. Paul Billings with ABC New Radio at CES 2012 about DNA Sequencing.

A radio interview with Dr. Paul Billings with ABC New Radio at CES 2012 about DNA Sequencing.

Over the past 6 years, next generation sequencing (NGS) has been established as a valuable high-throughput method for research in molecular genetics and has successfully been employed in the identification of rare and common genetic variations. All major NGS technology companies providing commercially available instruments (Roche 454, Illumina, Life Technologies) have recently marketed bench top sequencing instruments with lower throughput and shorter run times, thereby broadening the applications of NGS and opening the technology to the potential use for clinical diagnostics. Although the high expectations regarding the discovery of new diagnostic targets and an overall reduction of cost have been achieved, technological challenges in instrument handling, robustness of the chemistry and data analysis need to be overcome. To facilitate the implementation of NGS as a routine method in molecular diagnostics, consistent quality standards need to be developed. Here the authors give an overview of the current standards in protocols and workflows and discuss possible approaches to define quality criteria for NGS in molecular genetic diagnostics.

The view from the top of business. Presented by Evan Davis, The Bottom Line cuts through confusion, statistics and spin to present a clearer view of the business world, through discussion with people running leading and emerging companies. Evan and his guests discuss McDonald's. After a rocky period in the middle of the last decade, how well has the global burger chain managed to revive its famous fast-food formula? They also debate whether the progress of radical new technology has slowed down. Evan is joined in the studio by Greg Lucier, chief executive of US biotechnology company Life Technologies; Rita Clifton, chairman of branding consultancy Interbrand; Jill McDonald, chief executive of McDonald's UK. Producer: Ben Crighton.

Featuring - John Leamon, Ph.D. - Director of Molecular Biology at Ion Torrent Abstract - Dr. Leamon discusses one of the four Life Technologies Grand Challenges - the Ion Torrent Speed Challenge - where sample prep time is cut in half. John introduces a bit about DNA sample preparation, discusses automation, and offers some ideas to cut the time out of the DNA preparation process.

Featuring - John Leamon, Ph.D. - Director of Molecular Biology at Ion Torrent Abstract - Dr. Leamon discusses one of the four Life Technologies Grand Challenges - the Ion Torrent Speed Challenge - where sample prep time is cut in half. John introduces a bit about DNA sample preparation, discusses automation, and offers some ideas to cut the time out of the DNA preparation process.

Farnaz Khadem , Head of Corporate Communications and Public Relations for Life Technologies, gives her take on the Todd Buchholz keynote in terms of Global Technology and Education, plus she discusses her companys work in corporate communications and brand building.